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Abstract
Allergic asthma is a dysregulation of the immune system which leads to the development of Th2 responses to innocuous
antigens (allergens). Some infections and microbial components can re-direct the immune response toward the Th1
response, or induce regulatory T cells to suppress the Th2 response, thereby inhibiting the development of allergic asthma.
Since Acinetobacter baumannii infection can modulate lung cellular and cytokine responses, we studied the effect of A.
baumannii in modulating airway eosinophilia in a mouse model of allergic asthma. Ovalbumin (OVA)-sensitized mice were
treated with live A. baumannii or phosphate buffered saline (PBS), then intranasally challenged with OVA. Compared to PBS,
A. baumannii treatment significantly reduced pulmonary Th2 cytokine and chemokine responses to OVA challenge. More
importantly, the airway inflammation in A. baumannii-treated mice was strongly suppressed, as seen by the significant
reduction of the proportion and the total number of eosinophils in the bronchoalveolar lavage fluid. In addition, A.
baumannii-treated mice diminished lung mucus overproduction and pathology. However, A. baumannii treatment did not
significantly alter systemic immune responses to OVA. Serum OVA-specific IgE, IgG1 and IgG2a levels were comparable
between A. baumannii- and PBS-treated mice, and tracheobronchial lymph node cells from both treatment groups
produced similar levels of Th1 and Th2 cytokines in response to in vitro OVA stimulation. Moreover, it appears that TLR-4
and IFN-c were not directly involved in the A. baumannii-induced suppression of airway eosinophilia. Our results suggest
that A. baumannii inhibits allergic airway inflammation by direct suppression of local pulmonary Th2 cytokine responses to
the allergen.
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Introduction
Allergic asthma is a chronic, reversible airway inflammatory
disease of significant public health importance. Although the exact
mechanism is not clear, allergic asthma appears to result from
allergenspecifictype2T helper(Th2)lymphocyteproliferation with
concomitant excessive production of Th2 cytokines interleukin (IL)-
4, IL-5, IL-13 and/or IL-25 [1]. The allergen-specific Th2-like
immune responses include secretion of allergen specific IgE,
overproduction of bone marrow eosinophils, airway eosinophilia,
mucus secretion by goblet cells, and smooth muscle contraction, all
collectively contributing to airway hyperreactivity [2,3].
The gene-environment interaction seems to modulate the
aberrant immune responses to allergens, which leads to the
development and perpetuation of asthma [2]. In the last several
decades, the incidence of asthma has increased rapidly in both
developed and developing countries [4], with the estimated
number of asthmatic patients increasing from about 130 million
people in the mid-1990s to 330 million in 2008 [5,6]. However,
there are notable disparities in the prevalence of asthma between
developed and developing countries, and between urban and rural
areas of the same country [5]. It is postulated by the hygiene
hypothesis that improved living conditions (such as better hygiene
and reduced incidences of infectious diseases) in industrialized
countries and urban areas may somewhat contribute to the
development of allergic asthma [5,7].
According to the hygiene hypothesis, neonatal and early
childhood exposure to certain microbes and their products may
shift the immune response toward a Th1 phenotype, or activate
regulatory T cells and enhance IL-10 production, and thus
suppress the aberrant allergen-specific Th2 responses and alleviate
or inhibit the development of clinical symptoms of allergic asthma
[8–11]. This idea is supported by many experimental and clinical
studies with several microbes and their products [8–17].
Acinetobacter baumannii is a gram-negative, extracellular bacterium
that causes nosocomial and community-acquired pneumonia and
other infections [18]. Previous studies in our and other laboratories
have shown that intranasal (i.n.) administration of A. baumannii
induces acute bronchopneumonia characterized with neutrophil
infiltration at the first 72 h after infection [19,20], followed by
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the bacteria ,4 days after infection. Although allergic asthma is
primarily mediated by Th2-like immune responses, factors of the
innate immune system can play important roles in disease
initiation and progression. For example, as the ligand of TLR4,
LPS co-administration with allergens was found to either inhibit or
exacerbate the severity of asthmatic responses in mice [15].
Adoptive transfer of resident alveolar macrophages also inhibited
the airway hyperresponsiveness to OVA challenge in rats [21].
Since A. baumannii lung infection significantly modulates the host
innate immune response, we examined the effect of A. baumannii
infection/treatment of ovalbumin (OVA)-sensitized mice on the
development of airway eosinophilia and associated pulmonary
pathology upon subsequent OVA challenge, using a mouse model
of OVA-induced allergic asthma. Our results showed that A.
baumannii infection suppressed both OVA-specific Th1 and Th2
cytokine responses and the expression of eotaxins in the lung,
through a TLR-4 and IFN-c-independent mechanism. More
importantly, the infection suppressed airway eosinophilia and
associated lung pathology. The results of this study emphasize the
importance of infection-associated innate immune responses in the
regulation of the development of allergic asthma.
Materials and Methods
Mice
Six- to 8-week-old female C57BL/6 mice were purchased from
Charles River Laboratories (St. Constant, Quebec, Canada).
Female B6.129S7-Ifng
tm1Ts/J (IFN-c
2/2), C57BL/10ScNJ
(TLR4
2/2) and C57BL/10SnJ (TLR4
+/+) mice of a similar age
were purchased from Jackson Laboratories (Bar Harbor, ME,
USA). Mice were housed under specific pathogen-free conditions
in the Animal Resources, Institute for Biological Sciences,
National Research Council Canada (Ottawa) and given free
access to sterile water and ovalbumin (OVA)-free mouse chow.
The mice were housed and used in accordance with the
recommendations of the Canadian Council on Animal Care
Guide to the Care and Use of Experimental Animals. This study
and all animal care/use protocols were approved (ID # 2006.20
and 2007.15) by the Institute for Biological Sciences (National
Research Council Canada) Animal Care Committee.
Airway eosinophilia induction and A. baumannii
inoculation
Airway eosinophilia in the mouse model was induced as
described before [17] and is illustrated in Figure 1. Briefly, mice
were sensitized by intraperitoneal (i.p) injection of 2 mgO V A
(Sigma Chemical Co., St Louis, MO, USA) admixed in 100 ml
alum (Pierce Laboratories, Rockford, IL, USA) at day 0 and 14.
Seven days later (day 21), mice were treated by intranasal (i.n.)
administration (50 ml volume) of phosphate-buffered saline (PBS),
live A. baumanii (,10
8 CFU) in PBS, or formalin-fixed A.
baumannii (ffAb) in PBS (,10
8 CFU). Seven days post-treatment
(day 28), the mice were intranasally challenged with 100 mgO V A
in 50 ml of PBS. Five days after OVA challenge (day 33), the mice
were sacrificed and samples collected for various assays as
indicated below. For live A. baumannii treatment, fresh inocula
were prepared for each experiment from a frozen stock culture of
A. baumannii (ATCC 17961, American Type Culture Collection,
Manassas, VA) as described previously [20]. The actual treatment
concentration in each experiment was determined by plating 10-
fold serial dilutions on brain heart infusion (BHI) agar
supplemented with 50 mg/ml streptomycin. Our previous studies
showed that, at this infection dose (,10
8 CFU), A. baumannii is
generally cleared from the lungs in 4 days [20]. For obtaining the
formalin-fixed A. baumannii cells, the cells were fixed by overnight
incubation at 37uC in 10% neutral buffered formalin while gently
rotating the culture vessel, followed by 36 washing and
centrifugal harvesting in PBS.
Bronchoalveolar lavage (BAL) and histopathology
Mice were sacrificed five days after i.n. OVA challenge. Sera
were separated and stored at 280uC for antibody assays. The lungs
were lavaged five times with 1 ml PBS supplemented with 3 mM
EDTA and 1% fetal bovine serum [20]. Total lavage cell numbers
were enumerated using a haemocytometer, and differential cell
counts were determined on cytospin preparations stained with
Hema-3 stain set (Fisher Scientific, Middletown, VA, USA). BAL
fluid was centrifuged at 3,0006g for 7 min, and supernatants were
collected and stored at 280uC. In some experiments, the lungs were
removed immediately after lavage and immersed in 10% neutral
buffered formalin. The tissues were processed by standard paraffin
embedding methods (Department of Pathology and Laboratory
Medicine, University of Ottawa, Ottawa, Canada), sectioned (4 mm
thick), and stained with haematoxylin and eosin (H&E) or periodic
acid-Schiff (PAS) for histopathological evaluation. In some
experiments, the lungs from each mouse were minced into small
pieces using scissors, and homogenized in 2 ml of saline
supplemented with CompleteH protease inhibitors (Roche Diag-
nostics Canada, Laval, QC, Canada). The supernatant was
collected by centrifugation (3,0006g for 7 min) and stored at
280uC until used for cytokine assay.
Figure 1. Experimental protocol for the study. Mice were sensitized by i.p. administration of 2 mg ovalbumin admixed with 100 ml alum at day 0
and 14. At day 21, the mice were treated by i.n. administration (50 ml volume) of PBS, live A. baumannii (,10
8 CFU) or formalin-fixed (ff) A. baumannii
(,10
8 CFU). At day 28, mice were intranasally challenged with 100 mg OVA in 50 ml PBS or 50 ml PBS alone, as described in Material and Methods. Five
days after challenge (day 33), mice were sacrificed for sample collection.
doi:10.1371/journal.pone.0022004.g001
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polymerase chain reaction (qRT-PCR) for cytokine mRNA
expression
For RNA extraction, the lungs were immersed immediately in
RNAlaterH (Qiagen Inc., Valencia CA) and stored at 220uC.
Total RNA was extracted using TRIzol (Invitrogen Canada,
Burlington). Relative abundance of cytokine mRNA in lungs were
evaluated using a real-time RT-PCR-based method, as described
elsewhere [17]. Briefly, single stranded cDNA was prepared
through reverse transcription, cytokine genes were amplified and
quantified using primers and probes designed with the Primer3
program [22]. Levels of PCR products were normalized to the
housekeeping gene b-2-microglobulin (b2m), and data presented
as the average of relative expression values in A. baumannii-treated
mice compared with those in the corresponding tissues of PBS-
treated mice [17].
In vitro re-stimulation culture of tracheobronchial lymph
node (TBLN) cells
To assess in vitro cytokine responses to OVA stimulation, TBLNs
were collected for the preparation of single-cell suspensions (4610
6
cells/ml). TBLN cells were cultured in 48-well tissue culture plates
in RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) supplement-
ed with 10% heat-inactivated fetal bovine serum (Invitrogen,
Grand Island, NY, USA), 50 mM 2-mercaptoethanol (Sigma-
Aldrich), and 100 U/ml penicillin G and 100 mg/ml streptomycin
(Invitrogen). The cells were either stimulated with 1 mg/ml OVA
or medium alone. Culture supernatants were collected 72 h later
(5006g centrifugation for 10 min) and stored at 280uC for
cytokine assays.
Cytokine and chemokine assays
The levels of eotaxin-1, IFN-c, IL-4, IL-5, IL-10, IL-12p40, and
IL-13 in the BAL fluid and lung homogenate supernatants were
measured by the Milliplex mouse cytokine/chemokine kit
(Millipore, Billerica, MA) on a LuminexH 100IS system (Luminex
Corp, Austin, TX, USA) [23]. The analysis was done in duplicate,
and the cytokine concentrations were calculated against the
standards using BeadviewH software (ver. 1.03, Upstate). The
detection limit was ,2 pg/ml for IL-4, IL-10, and IL-13, 5.54 pg/
mL for IL-12p40, 8.97 pg/ml for IFN-c, and 30.9 pg/mL for IL-
5, respectively. IL-17A levels in the BAL fluid and lung
homogenates were determined by mouse IL-17A ELISA Ready-
Set-Go kit (eBioscience, San Diego, CA, USA), and the limit of
detection was 6 pg/ml.
Enzyme-linked immunosorbent assay (ELISA) for
ovalbumin-specific immunoglobulin isotype
Serum OVA-specific IgE were assayed using anti-IgE mAb-
(4B-39, BD Biosciences, Mississauga, Ontario, Canada) coated
microtiter plates, and detected by an ELISA assay using OVA-
biotin/streptavidin-horseradish peroxidase (HRP) in conjunction
with TMB substrate (KPL Inc., Gaithersburg, MD, USA). Serum
OVA-specific IgG1 and IgG2a were measured using OVA-coated
microtiter plates (Immulon 2, Thermo Labsystems, Franklin, MA,
USA) and detected using alkaline phosphatase conjugated goat
anti-mouse IgG1 or IgG2a, respectively (Caltag Laboratories,
Burlingame, CA, USA), in conjunction with pNPP substrate (KPL
Inc.) [24].
FACS analysis of regulatory T (Treg) cells
The percentages of Treg (CD4
+CD25
+Foxp3
+) cells in the BAL
fluid were determined by FACS analysis using the One Step
Staining Mouse Treg Flow
TM Kit (BioLegend, San Diego, CA).
Briefly, BAL cell samples were washed in PBS containing 1%
BSA. Aliquots containing ,10
6 cells were permeabilized using
fixation/permeabilization buffer, following the manufacturer’s
protocol, and then stained using Alexa FluorH 488 anti-mouse
FOXP3/CD25 PE/CD4 PerCP antibody cocktail or 20 ml Alexa
FluorH 488 rat IgG2b, k isotype control/CD25 PE/CD4 PerCP
antibody cocktail for 30 min at 4uC. After staining, the cells were
washed twice with the above PBS solution, and analyzed by FACS
Canto II flow cytometer (BD Biosciences, San Jose, CA) using
FACS Diva (BD Biosciences, San Jose, CA) software.
Statistical analyses
All parametric data are presented as mean 6 standard deviation
(SD) for each group. Differences between groups were analyzed by
Student’s t-test or by one-way and two-way ANOVA followed by
the Bonferroni multiple comparison test, when appropriate.
P,0.05 was considered to be statistically significant. All statistical
analyses were done using GraphPad Prism software (version 4.0,
GraphPad Software, San Diego, CA, USA).
Results
Acinetobacter baumannii infection inhibits airway
eosinophilia and associated pulmonary pathology in
OVA-sensitized/challenged mice
To examine the effect of A. baumannii infection on the
development of airway eosinophilia and associated pulmonary
pathology, groups of OVA-sensitized C57BL/6 mice were
intranasally inoculated with A. baumannii (A. baumannii treatment)
or PBS (PBS treatment) 3 weeks after sensitization. BAL fluid from
OVA-sensitized mice that had been treated with PBS prior to
challenging with OVA (OVA/PBS/OVA), had infiltration of large
numbers of eosinophils and mononuclear cells, as well as some
neutrophils (Figure 2). In contrast, i.n. inoculation of OVA-
sensitized mice with live A. baumannii prior to challenge with OVA
(OVA/A. baumannii/OVA) significantly inhibited eosinophil influx
into the bronchoalveolar space (P,0.001), without significantly
affecting the recruitment of the other cell types (neutrophils,
macrophages or lymphocytes), as compared with PBS-treated mice
(Figure 2). As expected, the BAL cells from OVA-sensitized and
i.n. PBS-challenged mice (OVA/PBS/PBS) contained predomi-
nantly (99%) alveolar macrophages (negative control).
We also examined the histopathogical changes in the lungs of
these mice. As shown in Figure 3, i.n. OVA challenge of the
sensitized mice treated with PBS (right panel) induced significant
perivascular and peribronchial infiltration of various types of
inflammatory cells, especially eosinophils, whereas OVA challenge
of A. baumannii-treated, sensitized mice substantially suppressed
inflammatory cell infiltration and associated pulmonary pathology
(left panel). Excess mucus secretion is an important pathophysi-
ological indicator of allergic asthma. Compared with PBS-treated
mice, the mice treated with A. baumannii had substantially reduced
mucus production by bronchial epithelial cells (Figure 3). These
results indicated that infection with A. baumannii significantly
inhibited the development of allergic airway eosinophilia and
associated pulmonary pathology in mice.
Several groups, including us, have previously shown that certain
crude or purified bacterial components (such as lipopolysaccha-
ride, LPS) can suppress allergic airway eosinophilia as effectively as
the live bacterial infection [9,14,15,17,25,26]. To examine this
possibility, OVA-sensitized mice were treated by i.n. administra-
tion of formalin-fixed A. baumannii (ffAb) before OVA challenge,
and the eosinophil responses were compared with those in mice
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BAL fluid from the PBS treatment group, BAL fluid from the ffAb
treatment group had ,50% lower eosinophil infiltration upon i.n.
OVA challenge (Figure 4). However, the live A. baumannii infection
suppressed pulmonary eosinophil responses by more than 90%,
compared to the PBS control treatment. These observations
indicate that although certain component(s) of A. baumannii can
partially suppress allergic airway inflammation, active infection is
necessary to maximize the inhibitory effect.
A. baumannii infection does not significantly alter serum
OVA-specific IgE and IgG subclass levels
Allergic asthma is generally recognized as a Th2-dependent
immune response with increased serum antigen-specific IgE and
IgG1 production [1,2]. As a first step to address the potential
mechanism of A. baumannii-induced inhibition of airway eosino-
philia, we examined the effect of i.n. treatment with live or
formalin-fixed A. baumannii on the changes in the serum IgE and
IgG subclasses (IgG1 and IgG2a). In agreement with published
reports [8,12,14,27], simply sensitizing mice with OVA-alum at 0
and 14 d (OVA/PBS/PBS group) induced only marginal levels of
OVA-specific IgE, IgG1 and IgG2a antibodies (Figure 5). As
expected, intranasal OVA challenge of the sensitized mice (OVA/
PBS/OVA) induced a remarkable increase in serum OVA-specific
IgG1, IgG2a, and IgE in sensitized mice. However, treatment of
sensitized mice with live or formalin-fixed A. baumannii showed no
significant effect on the serum OVA-specific IgE or IgG1 levels as
compared with PBS treatment group (Figure 5). The A. baumannii
treatment also showed no effect on the Th1-dependent OVA-
specific IgG2a levels (Figure 5).
Effect of i.n A. baumannii treatment on lung cytokine/
chemokine responses in allergic mice
It is well recognized that allergic airway eosinophilia and
inflammatory responses are regulated by multiple chemokines
[28–31] and Th2 cytokines [32–34]. To examine the effect of A.
baumannii on the cytokine/chemokine responses to OVA challenge
in OVA-sensitized mice, the mRNA expression of cytokine IFN-c
and IL-12p40 (Th1 associated), IL-4, IL-5, and IL-13 (Th2-
associated), and IL-10 (regulatory/suppressor function associated)
in the lungs, as well as their corresponding protein levels in the
BAL fluid and in lung homogenate supernatants were analyzed
from mice killed at day 5 after i.n OVA challenge. Compared with
PBS treatment, live A. baumannii treatment resulted in a substantial
reduction in IL-4, IL-5 and IL-13 mRNA expression, as well as
decreases in the mRNA expression of IFN-c, IL-10, and IL-12p40
Figure 2. Inhibition of airway eosinophilia in OVA-sensitized mice by live A. baumannii. Mice were sensitized by i.p. administration of OVA/
alum on days 0 and 14, then treated with A. baumannii or PBS on day 21, and intranasally challenged with OVA on day 28, as described in Fig. 1. Five
days after the i.n. OVA challenge, mice were euthanized, and their lungs were lavaged. Upper panel: Total and differential cell counts in the
bronchoalveolar lavage (BAL) fluid were enumerated on cytospin preparations. Each bar represents the mean total number of respective types of
cells in the BAL fluid 6 SD (n=5). The data presented represent 1 of at least 2 separate experiments with similar results. ***P,0.001. Lower panel: The
BAL cells from OVA-sensitized, PBS-challenged mice (A) consist of predominantly alveolar macrophages whereas the BAL cells from PBS-treated, OVA-
challenged mice (B) consist of mainly eosinophils (arrows) with a donut- or horseshoe-shaped nucleus and a pink granular cytoplasm. The majority of
BAL cells from A. baumannii-treated, OVA-challenged mice (C) are large alveolar macrophages (arrowheads) with a foamy cytoplasm. HemaStat-3
staining, bar=100 mm.
doi:10.1371/journal.pone.0022004.g002
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protein levels of these cytokines were also generally lower in the
lungs and BAL fluids of A. baumannii-treated mice as compared to
the PBS-treated mice, although these differences were only
statistically significant for IL-5 (P,0.05)(Figure 6B).
We also found that the mRNA expression of eotaxin 1 and
eotaxin 2, the key chemokines in the induction of eosinophil influx
into allergic tissue in mice and humans [28,31,32,35], was
markedly reduced in A. baumannii-infected mice, compared to the
high expression levels after OVA challenge in PBS-treated mice
(Figure 6A). Correspondingly, the level of eotaxin-1 in the lung
homogenates and, to a lesser degree in the BAL fluid was
significantly lower (P,0.05) in A. baumannii-infected mice
(Figure 6B).
To further examine the potential mechanism underlying the A.
baumannii-induced suppression of allergic airway eosinophilia, we
compared the cytokine responses to in vitro OVA re-stimulation of
TBLN cells obtained from PBS- or A. baumannii-treated, OVA
sensitized mice 5 days after an i.n. OVA challenge. As can be seen
in Figure 7, similar to the TBLN cells from PBS-treated mice, the
TBLN cells from A. baumannii-treated mice produced comparable
amounts of IFN-c, IL-10, IL-4, IL-5 and IL-13 in response to in
vitro OVA re-stimulation. The levels of IL-12p40 and eotaxin were
at the lower limit of detection. As expected, stimulation of TBLN
cells from both groups of mice with medium alone induced only
minimal amounts of cytokine production (Figure 7).
TLR4 or IFN-c is dispensable for A. baumannii-induced
inhibition of airway eosinophilia
Since A. baumannii is a gram-negative bacterium that contains
abundant amounts of LPS [36], we examined the potential
contribution of LPS in the A. baumannii-induced inhibition of
allergic airway eosinophilia, using TLR42/2 mice. In agreement
with previous observations [15,37,38], OVA-sensitized TLR42/
2 mice showed significantly higher airway eosinophil responses to
i.n OVA challenge than did the OVA-sensitized wild type mice,
suggesting that TLR4 signaling per se can efficiently suppress
OVA-induced airway inflammation. However, A. baumannii
Figure 3. Representative lung histopathology from OVA-sensitized mice treated with A. baumannii. The mice were sensitized and treated
as described in Figure 2 and killed 5 days after the OVA challenge. Note the severe pulmonary inflammation in the areas adjacent to various sized
airways in PBS-treated, OVA-sensitized/challenged mouse (arrows, top right panel) and the presence of large numbers of mucus-producing goblet
cells (dark purple) (bottom right panel) whereas the inflammation, goblet cell hyperplasia and mucus production were relatively minor in the lungs of
mice treated with A. baumannii (top left and bottom left panels). B=bronchus. Top panels stained with H&E; bottom panels stained with periodic
acid-Schiff, Bar=100 mm.
doi:10.1371/journal.pone.0022004.g003
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airway eosinophilia in both strains of mice (Figure 8). This result
indicates that A. baumannii-induced suppression of allergic airway
eosinophilia is independent of the TLR4 signaling pathway.
IFN-c is an important Th1 cytokine that down-regulates Th2
cytokine responses, and it has been implicated in the development
of allergic asthma [39–41]. We examined whether IFN-c plays a
role in A. baumannii-induced suppression of airway eosinophilia,
using IFN-c2/2 mice. In comparison with PBS-treated wild type
mice, the PBS-treated IFN-c2/2 mice displayed much stronger
airway eosinophilia following i.n. OVA challenge, suggesting a
general role for IFN-c in the suppression of the immune responses
to OVA challenge in OVA-sensitized mice (Figure 8). However,
airway eosinophilia in both IFN-c2/2 and wild type mice was
largely suppressed at a comparable magnitude after A. baumannii
treatment (Figure 8), suggesting that A. baumannii-induced
suppression of airway eosinophilia is not mediated by IFN-c.
Treg cells do not appear to mediate A.
baumannii-induced inhibition of airway eosinophilia
Microbes can suppress the Th2 response of allergic airway
eosinophilia through an elevated regulatory T cell response
[42,43]. We compared the number of Treg cells in BAL samples
by flow cytometry and found that although there was a more
remarkable increase in total BAL lymphocyte number in A.
baumannii-treated, allergic mice than sham-treated, allergic mice,
the percentage of Treg cells (defined as CD4
+CD25
+Foxp3
+) was
in fact lower in the A. baumannii-treated, allergic mice, than in
sham-treated, allergic mice (1.7% vs 11.9%, Figure 9). In addition,
the total number of Treg cells in the BAL of A. baumannii-treated,
allergic mice (1.1610
4 Treg cells) was actually lower than the
number of Treg cells in sham-treated, allergic mice (2.0610
4 Treg
cells) (data not shown), suggesting that A. baumannii-induced
suppression of airway eosinophilia is unlikely to be mediated
through Treg cell-associated suppression of Th2 responses.
Discussion
According to the hygiene hypothesis, exposure to microbes in
early childhood and throughout the life may modulate immune
responses during allergen stimulation, and prevent the develop-
ment of allergic asthma. Based on this theory, several clinical and
experimental studies that employed bacteria or bacterial compo-
nent(s) to prevent or treat asthma have shown some promising
results [9], while the mechanisms for such suppression remain
largely undefined. For example, Mycobacteria spp., the predomi-
Figure 4. Inhibition of airway eosinophilia in OVA-sensitized
mice by intranasal treatment with live or formalin-fixed A.
baumannii (ffAb). Mice were sensitized by i.p. administration with
OVA/alum on days 0 and 14. Sensitized mice were i.n. treated with
either 1610
8 CFU live or formalin-fixed A. baumannii on day 21 and i.n.
challenged with OVA on day 28. Cells in the bronchoalveolar lavage
(BAL) fluid were collected 5 days after OVA challenge and differential
cell types were enumerated on cytospin preparations. Each bar
represents the mean total numbers of respective types of cells in the
BAL fluid 6 SD (n=5). The data presented represent 1 of at least 2
separate experiments with similar results. ***P,0.001.
doi:10.1371/journal.pone.0022004.g004
Figure 5. OVA-specific serum IgG1, IgG2a, and IgE levels in
OVA-sensitized mice. Mice were OVA-sensitized as described in
Figure 2 and treated with PBS and challenged with PBS (OVA/PBS/
PBS),,treated with A. baumannii and challenged with OVA (OVA/A.
baumannii/OVA), treated with formalin-fixed A. baumanii and chal-
lenged with OVA (OVA/ffAb/OVA), or treated with PBS and challenged
with OVA (OVA/PBS/OVA). Groups of 5 mice were euthanized five days
after i.n. OVA challenge, and serum was collected. The OVA-specific
IgG1, IgG2a and IgE levels were measured using ELISA. Each data point
represents the mean OD value 6 SD of five mice in each group.
doi:10.1371/journal.pone.0022004.g005
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allergic asthma [8,12,14,42], may alleviate airway inflammation
by inducing different immune responses to allergens. Intranasal
administration of live BCG before OVA challenge suppressed IL-5
production and airway eosinophilia in an IFN-c dependent
manner [8], while subcutaneous treatment with killed M. vaccae
before OVA sensitization inhibited allergic airway inflammation
through the induction of a CD4
+CD45RB
lo regulatory T cell
secreted IL-10 and TGF-b [42]. Similarly, T cell-derived IL-10
has been found to be necessary to alleviate asthmatic symptoms
when dead mycobacteria or lipoglycan are administered before
OVA challenge [14]. Thus, bacterial suppression of allergic airway
inflammation and eosinophila may depend on the specific timing
of the administration, the route of administration, and the nature
of the microbes themselves. Microbes can modulate the allergic
airway eosinophilia by switching a predominantly Th2 phenotype
to a predominantly Th1 phenotype, or by suppressing the Th2
responses through elevated regulatory T cell response.
Acinetobacter baumannii is a ubiquitous Gram-negative, opportu-
nistic pathogen that frequently induces both nosocomial and
Figure 6. Cytokine responses in the lung and BAL fluid of OVA-
sensitized mice following OVA challenge. (A) Real-time PCR
analysis of cytokine mRNA expression in lung tissues in OVA-sensitized
and A. baumannii treated mice following i.n. OVA challenge. Mice were
sensitized and treated as described in Figure 2 and were euthanized 5
days after i.n. OVA challenge. The lungs were collected for RNA
extraction. Relative levels of cytokine mRNA expression were deter-
mined by real-time RT-PCR analysis as described in Materials and
methods. Mouse b-2 microglobulin RNA was measured and used to
calculate relative expression using the formula Rel Exp=2
2(DDCT).
Figure 7. Cytokine responses to in vitro re-stimulation of
tracheobronchial lymph node (TBLN) cells from A. baumannii-
treated mice. Groups of OVA-sensitized C57BL/6 mice were i.n.
treated with either A. baumannii or PBS 7 days before i.n. OVA
challenge. Mice were killed 5 days after the challenge and their TBLNs
were collected and used for in vitro culture to determine cytokine
production in response to OVA stimulation. Single cell suspensions
(4610
6 cells/mL) were re-stimulated in vitro for 48 h with either OVA
(1 mg/mL) or culture medium only. The cytokine levels in the
supernatants were determined by Luminex. Data are presented as
mean concentration (pg/ml) 6 SD (n=5), and are representative of two
independent experiments.
doi:10.1371/journal.pone.0022004.g007
Results shown are the average and ranges (error bars) of relative
expression values determined using cDNA from A. baumannii- or PBS-
treated, OVA challenged mice in relation to the corresponding
expression levels in PBS challenged mice (n=5 for all groups). (B)
Effect of A. baumannii infection on cytokine levels in BAL fluid and lung
homogenates in OVA-sensitized mice following i.n. OVA challenge. Mice
were sensitized and treated as described in Figure 2 and were
euthanized 5 days after i.n. OVA challenge. The levels of indicated
cytokines in BAL fluid and in the lung homogenate supernatants were
measured on a Luminex 100IS system using the Milliplex MAP mouse
cytokine/chemokine detection kit (Millipore). Each bar represents the
mean pg cytokine/mL 6 SD (n=5). The data are representative of two
to three independent experiments. *P,0.05 compared to the PBS-
treated group.
doi:10.1371/journal.pone.0022004.g006
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urinary tract infection and bacteremia [44–46]. A. baumannii
infection has recently emerged as a major cause of nosocomial
infections worldwide, likely because the bacteria can survive on the
surface of medical devices such as catheters and ventalitors, as well
as on the hands of hospital staff for extended periods of time, and
can easily spread through water droplets in the air [18,46].
Moreover, A. baumannii infections have become increasingly
difficult to treat because of the bacteria’s rapid development of
resistance to multiple antibiotics [18,47]. In this study, we found
that i.n. administration of live, and to a lesser extent, formalin
fixed A. baumannii significantly inhibited airway eosinophilia in
mice. Live A. baumannii treatment largely suppressed pulmonary
Th2 cytokines IL-4, IL-5 and IL-13 production, as well as
eosinophil-chemotactic chemokine eotaxin 1 and eotaxin 2.
However, levels of Th1 cytokines IL-12 and IFN-c in the lung
(BAL fluid and tissue homogenate supernatant) were not
significantly altered. Moreover, TBLN cells from A. baumannii -
and PBS-treated mice secreted similar amounts of cytokines upon
in in vitro stimulation, and the levels of serum OVA-specific IgE,
IgG1 and IgG2a were comparable. These results imply that A.
baumannii infection did not change systemic immune responses to
OVA from a Th2 to Th1 type, which is in contrast to several
previous studies with other bacterial species such as Chlamydia spp,
[48], Listeria monocytogenesis [10], and the live vaccine strain of
Francisella tularensis (LVS) [17]. Since A. baumannii is an extracellular
bacterium, it is likely that it may stimulate host immune responses
that are different than those induced by the intracellular bacteria
mentioned above. Indeed, several extracellular bacteria such as
Streptococcus pneumoniae and Bordetella pertussis alleviate airway
eosinophilia [25,26]. Compared to saline treatment, treatment of
mice with S. pneumoniae after OVA sensitization resulted in
significant reduction of OVA-specific Th2 cytokines IL-5 and
IL-13 responses by their TBLN cells without significant increases
in IFN-c production [25]. Similarly, administration of heat-killed
whole cell B. pertussis during sensitization and before OVA
challenge also significantly suppressed airway eosinophilia and
lung inflammation, which correlated with suppressed Th2
cytokine (IL-4 or IL-5) responses without the increased Th1
cytokine (IL-12 or IFN-c) levels [26]. It is not clear, however,
whether administration of this bacterium changed the systemic
immune responses. Similar to these extracellular bacteria, A.
baumannii-induced inhibition of airway eosinophilia is associated
with suppressed airway Th2 cytokine and chemokine production,
without the enhancement of Th1 responses. However, in contrast
to S. pneumoniae, A. baumannii treatment did not change the host
systemic immune responses to OVA. This is probably due to the
fact that pulmonary A. baumannii infection is acute and largely
limited to the lungs, and the infection may not be extensive and
persistent enough to modulate the systemic immune responses to
OVA. Moreover, using IFN-c2/2 mice, we demonstrated that
IFN-c is not essential for A. baumannii induced suppression of
allergic inflammation (Figure 8). The expression of IL-10 in lungs
or upon in vitro OVA stimulation of TBLN lymphocytes from A.
baumannii-treated mice also showed no differences in comparison
to those of PBS-treated control mice after OVA challenge. Real-
time RT-PCR results also indicated that pulmonary TGF-b
production was similar between PBS- or A. baumannii-treated mice.
In addition, we have demonstrated that A. baumannii-treated
allergic mice appear to have fewer, rather than more, Treg cells in
their BAL than do PBS-treated allergic mice (Figure 9). These
results suggest that regulatory T cells may not be involved in the
inhibition of allergic response by A. baumannii treatment. These
findings cumulatively suggest that A. baumannii-induced inhibition
of airway eosinophilia and associated pulmonary pathological
changes did not involve the systemic suppression of Th2 associated
factors or the elevation of Th1-specific parameters.
A. baumannii-induced alleviation of allergic airway inflammation
is not an isolated observation in the Acinetobacter species, since it has
been previously shown that i.n. treatment of mice with A. lwoffii
F78, a non-pathogenic Acinetobacter isolate cultured from farm
cowsheds, also suppressed airway eosinophilia and airway
hyperresponsiveness [49]. However, unlike A. baumannii, A. lwoffii
activates dendritic cells with increased expression of surface
activation markers CD40, CD80, CD86 and MHCII, and induces
highly Th1 polarizing immune responses including the enhanced
expression of delta-4 mRNA and increased secretion of IL-12
secretion, as well as reduced mRNA expression for Jagged-1 [49].
However, there is no information on whether the inhibition is
correlated with serum antibody levels/changes, or IL-4, 5, 13, and
IFN-c production. In our work, we used a clinically relevant
Figure 8. A. baumannii infection inhibits airway eosinophilia in
OVA-challenged TLR-42/2 and IFN-c2/2 mice. Knock out (KO)
and corresponding wild-type (WT) mice were sensitized i.p. with OVA/
alum on days 0 and 14 and treated with live A. baumannii or PBS as
described in Fig. 2. Mice were i.n. challenged with OVA on day 28. Cells
in the bronchoalveolar lavage (BAL) fluid were collected 5 days after
OVA challenge and different cell types were enumerated on cytospin
preparations. Each bar represents the mean total number of respective
types of cells per mouse lung 6 SD (n=5). *P,0.05 and ***P,0.001.
doi:10.1371/journal.pone.0022004.g008
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airway responses. Moreover, our study indicates that alleviated
airway inflammation in A. baumannii-treated mice is associated with
suppressed Th2 cytokine and chemokine eotaxin expression in the
lung. However, it is not entirely clear if A. lwoffii and A. baumannii
utilize fundamentally different immunoregulation mechanisms in
the inhibition of allergic airway eosinophilia, since the treatment
regime used in A. lwoffii studies was quite different from the present
study in that A. lwoffii treatment started 10 days before antigen
sensitization and continued every second day throughout the
whole sensitization and challenge phases of the study [49].
Our study showed that active infection with A. baumannii is not
essential for the inhibition of allergic airway eosinophilia, and
killed whole cells (formalin-fixed) are also capable of inhibiting the
development of airway eosinophila, although to a lesser extent
(Figure 4). A. baumannii is a gram-negative bacterium containing
abundant LPS, and recent studies have shown that earlier
childhood exposure to bacterial LPS is correlated with reduced
risk of atopy such as hay fever and allergic airway diseases [50].
Treatment of mice with Escherichia coli LPS suppresses the
development of airway hyperreactivity in mouse models of asthma
[15,37,38]. Since LPS has been implicated in the regulation of
allergic asthma development mainly through TLR-4 signalling
pathway [51], we studied the effect of A. baumannii administration
on allergic responses in TLR42/2 mice. Although PBS-treated
TLR-42/2 mice showed stronger airway eosinophilia than PBS-
treated wild type mice, indicating suppression of airway inflam-
mation by TLR-4 signaling, it is interesting to note that A.
baumannii treatment suppressed airway eosinophilia in both
TLR42/2 and wild type mice at a similar magnitude (Figure 8).
This result argues against a role for LPS in A. baumannii–induced
suppression of allergy airway eosinophilia. Instead, it suggests that
other components of A. baumannii may be more important in
suppression of OVA-specific inflammation.
A. baumannii infection per se induces strong inflammatory
responses and A. baumannii can cause substantial airway epithelial
damage via secretion of enzymes and toxic products leading to
oxidative stress and epithelial cell apoptosis [52]. As such, it is
possible that the reduction in most cytokines and inflammatory
cells assessed in A. baumannii-treated allergic mice versus PBS-
treated allergic mice could be due to increased epithelial cell
death. However, this is unlikely since we, and others, have
previously shown that i.n. A. baumannii infection at this dose
generally increases proinflammatory cytokine and chemokine
responses in the lungs [19,20]. Moreover, we also showed that
formalin-killed A. baumannii, which causes little or no damage to
the pulmonary epithelium, also inhibits airway eosinophilia
(Figure 4), making it unlikely that epithelial cell death is
responsible for the reduction in most cytokines and inflammatory
cells seen in this model.
In conclusion, administration of A. baumannii to mice that had
already been sensitized to OVA is capable of inhibiting airway
eosinophilia and associated pulmonary pathology. Our results
further support the observed role of microbes and their products
on the development/outcome of the pathogenesis of allergic
asthma. Future studies to examine the long term effect of
treatment, the use of inactivated bacterial cells, and particularly
the identification of effective bacterial component(s) should be
undertaken to explore A. baumannii as a potential immunomodu-
lator for the treatment of human allergic asthma.
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